OSTEOPOROZ U MUZhChIN: PODKhODY K TERAPII S SOVREMENNYKh POZITsIY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Osteoporosis (OP) in men is an important but poorly understood problem. One-third of all fractures of the proximal femur accounts for the male population, that determines high percentage of disability and premature mortality. OP in men may be primary (idiopathic, senile), or secondary, caused by hypogonadism, treatment with corticosteroids, alcohol uptake, vitamin D deficiency and inadequate calcium intake, or hormonal treatment of prostate cancer. There are differences in the approach to pharmacotherapy of OP in men and women. At present time, randomized clinical trials on the treatment of OP in men are insufficient. The use of bisphosphonates is the priority in the treatment of these patients.

Full Text

Restricted Access

References

  1. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int 1997;7:407-13.
  2. Chang KP, Center JR, Nguyen TV, et al. Incidence of hip and other osteoporotic fractures in elderly men and women: Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 2004;19:532-36.
  3. Cree M, Soskolne CL, Belseck E, et al. Mortality and institutionalization following hip fracture. Journal of the American Geriatrics Society 2000;48:283-88.
  4. Haentjens P, Magaziner J, Colon-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Annals of Internal Medicine 2010;152:380-90.
  5. Kannegaard PN, van der Mark S, Eiken P, et al. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age and Ageing 2010;39:203-9.
  6. Abrahamsen B, Brixen K. Mapping the prescriptiome to fractures in men - a national analysis of prescription history and fracture risk. Osteoporos Int 2009;20:585-97.
  7. O'Neill TW, Felsenberg D, Varlow J and The European Vertebral Osteoporosis Study Group. The prevalence of vertebral deformities in European men and women: The European Vertebral Osteoporosis Study. J Bone Miner Res 1996;11:1010-17.
  8. Klerk G, Hegeman JH, Bronkhorst P, et al. The (a)-Symptomatic Vertebral Fracture: A Frequently Discovered Entity with Clinical Relevance in Fracture Patients Screened on Osteoporosis. Geriatr Orthop Surg Rehabil 2012;3:74-8.
  9. Giangregorio LM, Macintyre NJ, Thabane L, et al. Exercise for improving outcomes after osteoporotic vertebral fracture. Cochrane Database Syst Rev 2013;1:18-20.
  10. Binkley N. Osteoporosis in men. Arq Bras Endocrinol Metabol 2006;50(4):764-74.
  11. Ebeling PR. Osteoporosis in Men. N Engl J Med 2008;358:1474-82.
  12. Kelepouris N, Harper KD, Gannon F, et al. Severe osteoporosis in men. Annals of Internal Medicine 1995; 123: 452-60.
  13. Abbasi AA, Rudman D, Wilson CR, et al. Observations on nursing home patients with a history of hip fracture. Am J Med Sci 1995;310:229-34.
  14. LeBlanc ES, Nielson CM, Marshall LM, et al. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in men. J Clin Endocrinol Metab. 2009;94:3337-46.
  15. Kawano H, Sato T, Yamada T, Matsumoto T, et al. Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci USA 2003;100:9416-21.
  16. Leslie WD, Lix LM. Simplified 10-year absolute fracture risk assessment: a comparison of men and women. J Clin Densitom 2009;13:141-46.
  17. Kaufman JM, Johnell O, Abadie E, et al. Background for studies on the treatment of male osteoporosis: state of the art. Annals Rheumatic Diseases 2000;59:765-72.
  18. Ryan CS, Petkov VI, Adler RA. Osteoporosis in men: the value of laboratory testing. Osteoporos Int 2011;22:1845-53.
  19. Szulc P, Kaufman JM, Delmas PD. Biochemical assessment of bone turnover and bone fragility in men. Osteoporosis Int 2007;18:1451-61.
  20. Nieves JW, Mosner M, Silverstein S. Osteoporosis. NY State Dent J 2012;78:30-5.
  21. Nelson B, Robert A, John P, et al. Osteoporosis in men: an Endocrine Society Clinical Practice Guidline. Journal of Clinical Endocrinology & Metabolism. 2012;97:1802-22.
  22. Baim S, Binkley N, Bilezikian, et al. Official positions of the international society for clinical densitometry and executive summary of the 2007 ISCD position development conference. J Clin Densitometry 2008;11:75-91.
  23. Clarke BL, Ebeling PR, Jones JD, et al, Predictors of bone mineral density in aging healthy men varies by skeletal site. Calcif Tissue Int 2002;70:137-45.
  24. Vallarta-Ast N, Krueger D, Binkley N. An evaluation of forearm BMD measurement for diagnosis and treatment monitoring in men. J Bone Mineral Res 2007;22:300.
  25. Eric S, Orwoll J, et al. Osteoporosis in men.Elsevier, 2010:698.
  26. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385-97.
  27. Sinaki M, Pfeifer M, Preisinger E, et al. The role of exercise in the treatment of osteoporosis. Curr Osteoporos Rep 2010;8:138-44.
  28. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;25(370): 657-66.
  29. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10.
  30. Boonen S, Orwoll ES, Wenderoth D, et al. Onceweekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 2009;24:719-25.
  31. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809.
  32. Ho YV, Frauman AG, Thomson W, et al. Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int 2000;11:98-101.
  33. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-99.
  34. Ringe JD, Faber H, Dorst A. Alendronate Treatment of Established Primary Osteoporosis in Men: Results of a 2-Year Prospective study. J Clin Endocrinol Metab, November 2001, 86(11):5252-55.
  35. Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1- year study. Rheumatol Int 2006;26:427-31.
  36. Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002;24(11):1871-86.
  37. Orwoll E, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18:9-17.
  38. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005;16:510.
  39. Kaufman JM, Audran M, Bianchi G, et al. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 2013;98(2):592-601.
  40. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgendeprivation therapy for prostate cancer. N Engl J Med 2009;361:745-55.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies